X4 Pharmaceuticals (XFOR) Gross Profit (2024 - 2025)
X4 Pharmaceuticals posted quarterly Gross Profit of $2.2 million for Q4 2025, up 94.7% year-on-year from $1.1 million in Q4 2024, and up 55.87% on a QoQ basis from $1.4 million in Q3 2025.
X4 Pharmaceuticals (XFOR) has 2 years of Gross Profit data on file, last reported at $2.2 million in Q4 2025.
- For the quarter ending Q4 2025, Gross Profit rose 94.7% year-over-year to $2.2 million; the trailing twelve-month figure through Dec 2025 stood at $29.4 million (up 1567.95% YoY), and the FY2025 full-year result was $29.4 million, up 1567.95% from the prior year.
- Gross Profit for Q4 2025 stood at $2.2 million, up from $1.4 million in the prior quarter.
- Across five years, Gross Profit topped out at $24.1 million in Q1 2025 and bottomed at $295000.0 in Q2 2024.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn |
| 10 | X4 Pharmaceuticals | 182.28 Mn | 182.28 Mn | 2.20 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 2.20 Mn |
| Dec 31, 2025 | 2.20 Mn |
| Sep 30, 2025 | 1.41 Mn |
| Sep 30, 2025 | 1.41 Mn |
| Jun 30, 2025 | 1.65 Mn |
| Jun 30, 2025 | 1.65 Mn |
| Mar 31, 2025 | 24.09 Mn |
| Mar 31, 2025 | 24.09 Mn |
| Dec 31, 2024 | 1.13 Mn |
| Dec 31, 2024 | 1.13 Mn |
| Sep 30, 2024 | 333,000.00 |
| Sep 30, 2024 | 333,000.00 |
| Jun 30, 2024 | 295,000.00 |
| Jun 30, 2024 | 295,000.00 |